|
Dermatologic disorders
|
0.310 |
Biomarker
|
group |
BEFREE |
The expression of various DC markers, MIP-3α, and E-cadherin in the tissue samples obtained from patients with warts, HPV-Bowen and HPV-unrelated skin diseases was evaluated by immunohistochemistry.
|
21715145 |
2011 |
|
Dermatologic disorders
|
0.310 |
Biomarker
|
group |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Mammary Neoplasms
|
0.310 |
Biomarker
|
group |
BEFREE |
These results reveal a role for CCL20 also in tumor breast cell and point to CCL20 as a novel therapeutic target in cancer.
|
28618084 |
2017 |
|
Mammary Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Colonic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
|
15059925 |
2004 |
|
Hypersensitivity
|
0.300 |
Biomarker
|
group |
CTD_human |
Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression.
|
21625544 |
2011 |
|
Inflammatory Bowel Diseases
|
0.180 |
Biomarker
|
group |
BEFREE |
Expression of CCR6 and its ligand, CCL20, are increased in the colon of humans with inflammatory bowel diseases and mice with experimental colitis; however, their role in disease pathogenesis remains obscure.
|
20720211 |
2010 |
|
Inflammatory Bowel Diseases
|
0.180 |
Biomarker
|
group |
BEFREE |
Considering the role of Ccl20 and Toll-like receptor 9 (TLR9) in gut homeostasis and inflammatory bowel disease (IBD), regulation of Ccl20 by bacterial DNA, the TLR9 ligand, merits in-depth studies.
|
27590109 |
2017 |
|
Inflammatory Bowel Diseases
|
0.180 |
AlteredExpression
|
group |
BEFREE |
Therefore, analysis of CCL20 expression in PBMC may be used as a surrogate measure for evaluation of IBD activity, disease progression and therapeutic efficacy in Chinese IBD patients.
|
20064082 |
2010 |
|
Inflammatory Bowel Diseases
|
0.180 |
Biomarker
|
group |
BEFREE |
We demonstrate that IL-33, GLP-1R, and CCL20 are deregulated in human IBD, and that prophylactic treatment with 0.6 mg/kg liraglutide improves disease in AdTr colitis.
|
27542128 |
2016 |
|
Inflammatory Bowel Diseases
|
0.180 |
Biomarker
|
group |
BEFREE |
TNF-alpha increased and anti-TNF-alpha decreased CCL20 release in healthy control CEC but not in involved IBD colonic specimens.
|
14997037 |
2004 |
|
Inflammatory Bowel Diseases
|
0.180 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.
|
28067908 |
2017 |
|
Inflammatory Bowel Diseases
|
0.180 |
Biomarker
|
group |
BEFREE |
The chemokine CCL20 and its receptor CCR6 are putative drug targets in inflammatory bowel disease, and CCL20 is a novel IBD predilection gene.
|
26536229 |
2015 |
|
Inflammatory Bowel Diseases
|
0.180 |
Biomarker
|
group |
BEFREE |
Recently, numerous new genes have been identified to be involved in the genetic susceptibility to IBD: NOD1/Caspase-activation recruitment domains 4 (CARD4), Chemokine ligand 20 (CCL20), IL-11, and IL-18 among others.
|
17948929 |
2007 |
|
Inflammatory Bowel Diseases
|
0.180 |
AlteredExpression
|
group |
BEFREE |
Serum IL-17C levels are modified by IL23R genotypes and IL-17C mRNA correlates (r>0.5, P<0.001) with IL-17A, tumor necrosis factor (TNF)-α, C-C motif chemokine ligand 20 (CCL20) and IL-23 mRNA in the inflamed colon of IBD patients.
|
25492478 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The findings of the present study suggest that the recruitment and activation of DC in vivo due to the synergistic actions of pGM-CSF and pMIP3α presents a potentially feasible means of controlling immunogenic malignancies and provides a basis for the development of novel immunotherapeutic treatments.
|
20804501 |
2010 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The levels of CCL20 and CCR6 are elevated in many human cancers, and CCL20/CCR6 interaction participates in the development and progression of cancer.
|
24984269 |
2014 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The disruption of CCL20/CCR6 interactions may be a promising strategy for the treatment of cancer.
|
29250193 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, these data show that therapeutic cancer vaccines can be potentiated by the combined nanoparticle mediated co-delivery of poly (I:C), R848 and MIP3α, which indicates that a more favorable milieu for cancer fighting immune cells is created for T cells induced by therapeutic cancer vaccines.
|
31419588 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human oral squamous cell carcinoma (OSCC) constitutes an inflammatory microenvironment enriched with chemokines such as CCL20, which promote cancer cell invasion and tumor progression.
|
28600287 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results reveal a role for CCL20 also in tumor breast cell and point to CCL20 as a novel therapeutic target in cancer.
|
28618084 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CCL20 and its receptor CCR6 have been shown to play a role in the onset, development and metastatic spread of various gastrointestinal malignancies.
|
20459729 |
2010 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, CCL20 and its only receptor (CCR6) are exploited by cancer cells for migration and metastatic spread and play important roles in the development and progression of cancer.
|
25130722 |
2014 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High level expression of CCL20 and its receptor CCR6 in HCC and CRLM with marked up-regulation of CCL20 in CRLM in relation to HCC tissues indicates involvement of the CCL20/CCR6 ligand-receptor pair in the carcinogenesis and progression of hepatic malignancies.
|
17075975 |
2006 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that the cancer secretome decreases Ccl20 secretion from TAF by activation of JNK, and downregulation of Ccl20 secretion might be correlated with reduction of infiltrating CD8<sup>+</sup> T cells.
|
28837246 |
2017 |